See more : Meridian Bancorp, Inc. (EBSB) Income Statement Analysis – Financial Results
Complete financial analysis of Novartis AG (NVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novartis AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Guomai Technologies, Inc. (002093.SZ) Income Statement Analysis – Financial Results
- Manx Financial Group PLC (MFX.L) Income Statement Analysis – Financial Results
- Cleantek Industries Inc. (GLKFF) Income Statement Analysis – Financial Results
- The AES Corporation (AES) Income Statement Analysis – Financial Results
- RENK Group AG (R3NK.BE) Income Statement Analysis – Financial Results
Novartis AG (NVS)
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.14B | 49.44B | 50.39B | 53.63B | 58.83B | 57.56B | 59.38B | 51.56B | 45.10B | 42.58B | 38.95B | 36.75B | 32.53B | 28.25B | 24.86B | 23.15B | 19.34B | 21.83B | 20.42B | 23.04B |
| Cost of Revenue | 12.47B | 15.49B | 15.87B | 15.12B | 14.43B | 18.41B | 17.18B | 17.52B | 17.40B | 17.35B | 19.61B | 18.76B | 18.98B | 14.49B | 12.18B | 11.44B | 11.03B | 10.30B | 8.87B | 6.63B | 5.89B | 5.44B | 4.76B | 6.25B | 5.23B | 7.31B |
| Gross Profit | 34.19B | 36.34B | 37.01B | 34.78B | 34.25B | 34.76B | 32.96B | 31.92B | 32.98B | 36.29B | 39.22B | 38.81B | 40.39B | 37.07B | 32.92B | 31.15B | 27.92B | 26.45B | 23.66B | 21.62B | 18.97B | 17.71B | 14.58B | 15.59B | 15.19B | 15.73B |
| Gross Profit Ratio | 73.27% | 70.12% | 69.99% | 69.70% | 70.37% | 65.38% | 65.74% | 64.56% | 65.46% | 67.66% | 66.67% | 67.42% | 68.03% | 71.90% | 73.00% | 73.14% | 71.67% | 71.97% | 72.74% | 76.55% | 76.30% | 76.50% | 75.39% | 71.40% | 74.39% | 68.29% |
| Research & Development | 11.37B | 10.00B | 9.54B | 8.98B | 9.40B | 9.07B | 8.97B | 9.04B | 8.94B | 9.09B | 9.85B | 9.33B | 9.58B | 9.07B | 7.47B | 7.22B | 6.43B | 5.35B | 4.85B | 4.21B | 3.76B | 3.10B | 2.53B | 2.84B | 2.67B | 2.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.47B | 2.14B | 2.19B | 2.48B | 2.62B | 3.06B | 2.94B | 2.97B | 2.48B | 2.28B | 2.25B | 2.13B | 1.96B | 1.74B | 1.54B | 0.00 | 8.98B | 7.66B | 7.94B | 6.95B | 1.29B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.86B | 12.00B | 11.77B | 12.38B | 14.55B | 14.35B | 15.08B | 13.32B | 12.05B | 11.85B | 11.13B | 10.45B | 9.80B | 8.87B | 9.33B | 0.00 | 0.00 | 0.00 | 0.00 | 6.39B |
| SG&A | 12.49B | 14.25B | 14.89B | 14.20B | 14.37B | 16.47B | 15.00B | 14.19B | 14.25B | 14.99B | 17.61B | 17.29B | 18.05B | 15.80B | 14.33B | 14.10B | 13.26B | 12.41B | 11.54B | 10.41B | 9.33B | 8.98B | 7.66B | 7.94B | 6.95B | 7.68B |
| Other Expenses | 559.00M | 2.90B | 895.00M | 1.45B | 1.40B | 1.05B | 362.00M | 417.00M | 824.00M | 1.12B | 852.00M | 672.00M | 1.76B | 680.00M | 1.14B | 867.00M | 1.45B | 741.00M | 363.00M | 463.00M | 0.00 | 0.00 | 0.00 | 0.00 | 949.00M | 0.00 |
| Operating Expenses | 24.42B | 27.15B | 25.32B | 24.63B | 25.17B | 26.59B | 24.33B | 23.65B | 24.01B | 25.20B | 28.31B | 27.29B | 29.39B | 25.55B | 22.94B | 22.18B | 21.13B | 18.50B | 16.75B | 15.08B | 13.08B | 12.08B | 10.18B | 10.78B | 10.57B | 10.39B |
| Cost & Expenses | 36.89B | 42.63B | 41.19B | 39.75B | 39.59B | 45.00B | 41.51B | 41.17B | 41.41B | 42.55B | 47.92B | 46.05B | 48.38B | 40.04B | 35.12B | 33.62B | 32.17B | 28.80B | 25.62B | 21.71B | 18.98B | 17.52B | 14.94B | 17.03B | 15.80B | 17.69B |
| Interest Income | 627.00M | 379.00M | 71.00M | 91.00M | 245.00M | 294.00M | 110.00M | 43.00M | 33.00M | 33.00M | 34.00M | 50.00M | 62.00M | 103.00M | 156.00M | 306.00M | 423.00M | 367.00M | 405.00M | 388.00M | 323.00M | 416.00M | 293.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 855.00M | 837.00M | 811.00M | 869.00M | 850.00M | 957.00M | 777.00M | 707.00M | 655.00M | 704.00M | 683.00M | 724.00M | 751.00M | 692.00M | 551.00M | 290.00M | 237.00M | 266.00M | 294.00M | 261.00M | 243.00M | 259.00M | 218.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28B | 6.71B | 5.43B | 5.11B | 5.83B | 5.21B | 5.21B | 5.35B | 5.58B | 4.75B | 4.99B | 4.95B | 5.79B | 3.42B | 2.30B | 2.67B | 2.86B | 1.99B | 1.72B | 1.34B | 1.28B | 690.00M | 585.00M | 918.00M | 949.00M | 1.01B |
| EBITDA | 18.29B | 14.73B | 17.13B | 15.24B | 15.01B | 14.14B | 13.90B | 13.19B | 14.36B | 17.66B | 15.90B | 16.92B | 17.09B | 15.81B | 12.77B | 12.46B | 10.58B | 10.18B | 8.78B | 7.97B | 7.26B | 5.90B | 4.41B | 5.63B | 5.56B | 6.35B |
| EBITDA Ratio | 39.19% | 31.62% | 62.52% | 34.49% | 32.08% | 40.91% | 31.71% | 30.42% | 28.51% | 33.05% | 27.89% | 29.40% | 29.20% | 30.67% | 28.18% | 28.96% | 26.75% | 28.62% | 28.21% | 29.63% | 29.21% | 25.50% | 22.82% | 24.68% | 25.46% | 27.58% |
| Operating Income | 9.77B | 9.20B | 26.95B | 10.15B | 9.09B | 8.17B | 8.63B | 8.27B | 8.98B | 11.09B | 10.91B | 11.51B | 11.00B | 11.53B | 9.98B | 8.96B | 6.78B | 7.95B | 6.91B | 6.54B | 5.89B | 5.63B | 4.39B | 4.81B | 4.62B | 5.35B |
| Operating Income Ratio | 20.94% | 17.75% | 50.96% | 20.35% | 18.67% | 15.37% | 17.21% | 16.72% | 17.82% | 20.68% | 18.54% | 20.00% | 18.52% | 22.35% | 22.13% | 21.05% | 17.41% | 21.63% | 21.23% | 23.15% | 23.68% | 24.34% | 22.72% | 22.01% | 22.62% | 23.20% |
| Total Other Income/Expenses | -646.00M | 425.00M | -16.15B | -274.00M | -146.00M | -746.00M | -811.00M | -451.00M | -843.00M | 1.18B | -176.00M | -271.00M | -225.00M | 176.00M | -60.00M | 94.00M | 294.00M | -219.00M | 360.00M | -129.00M | -155.00M | 64.00M | 367.00M | 789.00M | 714.00M | 408.43M |
| Income Before Tax | 9.12B | 8.37B | 26.14B | 9.88B | 8.94B | 13.84B | 9.00B | 7.82B | 8.13B | 12.27B | 10.74B | 11.24B | 10.77B | 11.70B | 9.92B | 9.50B | 7.49B | 8.30B | 7.27B | 6.91B | 6.07B | 6.29B | 5.11B | 5.51B | 5.34B | 5.79B |
| Income Before Tax Ratio | 19.55% | 16.15% | 49.43% | 19.80% | 18.37% | 26.02% | 17.95% | 15.81% | 16.14% | 22.88% | 18.25% | 19.53% | 18.14% | 22.70% | 22.00% | 22.31% | 19.22% | 22.59% | 22.34% | 24.46% | 24.40% | 27.17% | 26.42% | 25.22% | 26.16% | 25.14% |
| Income Tax Expense | 551.00M | 1.42B | 2.12B | 1.81B | 1.79B | 1.22B | 1.30B | 1.12B | 1.11B | 1.55B | 1.44B | 1.63B | 1.53B | 1.73B | 1.47B | 1.34B | 947.00M | 1.28B | 1.12B | 1.13B | 1.01B | 1.07B | 869.00M | 1.11B | 1.15B | 1.37B |
| Net Income | 14.85B | 6.96B | 24.02B | 8.07B | 7.15B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B | 9.18B | 9.51B | 9.11B | 9.79B | 8.40B | 8.20B | 11.95B | 7.18B | 6.13B | 5.77B | 5.02B | 5.22B | 4.24B | 4.40B | 4.19B | 4.41B |
| Net Income Ratio | 31.83% | 13.42% | 45.43% | 16.18% | 14.68% | 23.72% | 15.36% | 13.58% | 35.29% | 19.04% | 15.60% | 16.51% | 15.35% | 18.99% | 18.62% | 19.24% | 30.67% | 19.52% | 18.85% | 20.42% | 20.17% | 22.56% | 21.92% | 20.13% | 20.51% | 19.13% |
| EPS | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 | 3.76 | 3.93 | 3.75 | 4.28 | 3.70 | 3.62 | 5.15 | 3.06 | 2.63 | 2.28 | 1.99 | 1.88 | 1.49 | 1.70 | 0.62 | 0.33 |
| EPS Diluted | 7.10 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.80 | 7.29 | 4.13 | 3.70 | 3.89 | 3.70 | 4.26 | 3.69 | 3.59 | 5.13 | 3.04 | 2.62 | 2.27 | 1.97 | 1.84 | 1.49 | 1.70 | 0.62 | 0.33 |
| Weighted Avg Shares Out | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B | 2.40B | 2.43B | 2.44B | 2.42B | 2.38B | 2.29B | 2.27B | 2.27B | 2.32B | 2.35B | 2.33B | 2.36B | 2.38B | 2.52B | 2.57B | 2.63B | 2.62B | 2.74B |
| Weighted Avg Shares Out (Dil) | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B | 2.44B | 2.47B | 2.48B | 2.44B | 2.41B | 2.30B | 2.28B | 2.28B | 2.33B | 2.36B | 2.34B | 2.37B | 2.41B | 2.57B | 2.58B | 2.63B | 2.62B | 2.74B |
Novartis (NVS) Upgraded to Buy: Here's What You Should Know
Novartis (NVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Novartis' Cholesterol Drug Meets Primary Goals in Late-Stage Study
NVS' late-stage study meets its primary endpoints, demonstrating the superiority of Leqvio monotherapy over both placebo and ezetimibe in LDL-C reduction.
Novartis twice-yearly* Leqvio® demonstrated clinically meaningful, statistically significant LDL-C lowering as a monotherapy in patients at low or moderate ASCVD risk
Basel, August 28, 2024 – Novartis announced today positive topline results from twice-yearly* Leqvio® (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. Leqvio monotherapy achieved clinically meaningful and statistically significant low-density lipoprotein cholesterol (LDL-C) lowering versus...
Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
Galapagos stock surged Monday after the Food and Drug Administration cleared the biotech company to begin testing its cancer drug in people.
Siemens Healthineers to buy Novartis unit for over $223 million, FT reports
Siemens Healthineers will pay more than 200 million euros ($223.8 million) to acquire the diagnostic arm of Advanced Accelerator Applications, owned by Novartis , the Financial Times reported on Saturday.
Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings
In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk...
2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
Despite DexCom's recent challenges, it still has ample growth opportunities. Novartis is a reliable dividend payer that recently changed its business for the better.
Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?
Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.
Novartis loses initial bid to block generic of best-selling heart drug
Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday.
10 High-Yield Dividend Aristocrats That Could Be Perfect For What's Coming Next
Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%....
Source: https://incomestatements.info
Category: Stock Reports